Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Sunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market | 138 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas... ► Artikel lesen | |
SUNSHINE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
21.01. | Sunshine Biopharma introduces new generic drugs in Canada | 6 | Investing.com | ||
21.01. | Sunshine Biopharma Inc.: Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT | 205 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety... ► Artikel lesen | |
15.01. | Sunshine Biopharma names new Chief Commercial Officer | 2 | Investing.com | ||
15.01. | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer | 174 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
15.01. | Sunshine Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.01. | Sunshine Biopharma files $100M mixed securities shelf | 2 | Seeking Alpha | ||
10.12.24 | Sunshine Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
09.12.24 | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus | 284 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
04.12.24 | Sunshine Biopharma, Inc.: Sunshine Biopharma Launches a New Generic Prescription Drug | 266 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / December 4, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
02.12.24 | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma | 222 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
22.11.24 | Sunshine Biopharma bringt generisches Lebermedikament in Kanada auf den Markt | 7 | Investing.com Deutsch | ||
22.11.24 | Sunshine Biopharma launches generic liver drug in Canada | 2 | Investing.com | ||
22.11.24 | Sunshine Biopharma, Inc.: Sunshine Biopharma Launches a New Generic Prescription Drug | 325 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
07.11.24 | Sunshine Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
06.11.24 | Sunshine Biopharma reports Q3 results | 1 | Seeking Alpha | ||
06.11.24 | Sunshine Biopharma, Inc.: Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% | 406 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
05.11.24 | Sunshine Biopharma Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
23.10.24 | Sunshine Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.10.24 | Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 66.8% in September | 1 | MarketBeat |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CASSAVA SCIENCES | 2,506 | -2,07 % | CASSAVA SCIENCES INC - 8-K, Current Report | ||
ORAMED PHARMACEUTICALS | 2,210 | +0,23 % | Oramed Aktie: Besorgniserregende Signale? | Die Oramed Pharmaceuticals Aktie verzeichnete am 22. Februar 2025 einen signifikanten Rückgang. Der Aktienkurs fiel um 3,15 Prozent auf 2,15 USD, was einem Minus von 0,07 USD gegenüber dem vorherigen... ► Artikel lesen | |
SCYNEXIS | 0,789 | -8,52 % | SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update | The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted... ► Artikel lesen | |
CITIUS PHARMACEUTICALS | 1,500 | -2,60 % | Citius Pharmaceuticals, Inc. - 8-K, Current Report | ||
LIPOCINE | 3,280 | -0,61 % | Lipocine Inc.: Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 | SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
NRX PHARMACEUTICALS | 2,160 | +16,76 % | NRX Pharmaceuticals, Inc. - 10-K, Annual Report | ||
ALLERGY THERAPEUTICS | 0,075 | +1,36 % | Allergy Therapeutics - New Executive Long Term Incentive Awards | ||
REVIVA PHARMACEUTICALS | 1,115 | +7,21 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
BAYER | 23,285 | +1,68 % | Bayer AG: Kapitalerhöhungsermächtigung schürt Ängste; mwb research bekräftigt KAUFEN | Bayers Aktie stürzte ab, nachdem das Unternehmen Pläne für eine Kapitalerhöhungsermächtigung um 35 % auf seiner Hauptversammlung im April 2025 angekündigt hatte, was die Sorgen der Investoren weiter... ► Artikel lesen | |
MERCK KGAA | 134,45 | +0,04 % | EQS-HV: MERCK Kommanditgesellschaft auf Aktien: Bekanntmachung der Einberufung zur Hauptversammlung am 25.04.2025 in Darmstadt mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: MERCK Kommanditgesellschaft auf Aktien
/ Bekanntmachung der Einberufung zur Hauptversammlung
MERCK Kommanditgesellschaft auf Aktien: Bekanntmachung der Einberufung zur... ► Artikel lesen | |
GSK | 18,080 | +0,42 % | GSK PLC - Director/PDMR Shareholding | ||
NOVO NORDISK | 71,09 | +0,14 % | Statt dicker Gewinne: Novo Nordisk kriegt schon wieder sein Fett weg! | © Foto: Christian Schultz/dpaNovo Nordisk enttäuscht abermals mit Studiendaten. Die Anleger lassen das dänische Unternehmen abermals fallen.Novo Nordisk hat am Montag neue Daten aus einer zweiten späten... ► Artikel lesen | |
DERMAPHARM | 39,000 | +2,63 % | Ihre wichtigsten Termine: Spannende Updates von: BMW, Dermapharm, Daimler Truck, Allianz und Bechtle | © Foto: Frank Rumpenhorst/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
PFIZER | 23,650 | +0,11 % | Arvinas, Pfizer Report Positive Topline Data From Phase 3 VERITAC-2 Study | NEW YORK CITY (dpa-AFX) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) Tuesday announced positive topline results from the Phase 3 VERITAC-2 study.The study is designed to evaluate the companies'... ► Artikel lesen | |
SCHOTT PHARMA | 23,900 | +0,67 % | Leichter Wertverlust bei der Schott Pharma-Aktie (24,90 €) | Der Anteilsschein von Schott Pharma notiert heute leichter. Das Papier notiert derzeit bei 24,90 Euro. Ein Verlust von 1,97 Prozent steht gegenwärtig für die Schott Pharma-Aktie zu Buche. Das Wertpapier... ► Artikel lesen |